AAA
SYRS

Affinity Asset Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Affinity Asset Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,541,200
Closed -$354K – 116
2024
Q4 		$354K Buy
1,541,200
+307,000
+25% +$368K 0.05% 76
2024
Q3 		$2.65M Buy
+1,234,200
New +$4.43M 0.36% 59

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Affinity Asset Advisors's SYRS Position: Q1 2025 in Review

Affinity Asset Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 150,000 shares — an estimated $34.5K sold.

Affinity Asset Advisors first reported a position in SYRS in Q4 2024 and held it in 1 quarter. The position peaked at $34.5K in Q4 2024. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Affinity Asset Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 150,000 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $34.5K.
  • Affinity Asset Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
  • Affinity Asset Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $34.5K in Q4 2024.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Affinity Asset Advisors's 13F filing for Q1 2025, filed 14 May 2025.